title: [GLP-1 analogues in treatment of type 1 diabetes mellitus].
abstract: BACKGROUND
  The insulin replacement is essential in the treatment of type 1 diabetes. Insulin therapy has been coupled with relevant side effects such as hypoglycemia and weight gain. Glucagon-like Peptide 1(GLP-1) analogues (liraglutide) and incretin mimetics (exenatide) are approved only for the treatment of type 2 diabetes mellitus. This review aims to answer the question of what effects exercise GLP-1 analogues on glucose metabolism in people with type 1 diabetes mellitus.
  
  
  METHODS
  A systematic literature search. We included studies in people with diabetes mellitus type 1 and GLP-1 analogues intervention. The report quality, the methodological quality of the studies and reviews was based on CONSORT and PRISMA assessed.
  
  
  RESULTS
  A total of 19 potentially relevant publications 219 hits were identified. Included were four randomized-controlled trials, two non-randomized-controlled trials and five reviews. The studies and reviews have shown a different methodological quality. There were significant changes in insulin dose (p ≤ 0.01) reduced Hyperglykämierate detected (p ≤ 0.01) reduction of blood glucose variations (p ≤ 0.01) and a reduction in glucagon (p ≤ 0.05).
  
  
  CONCLUSIONS
  The delayed gastric emptying and reduction of glucagon is the main mechanism of the improved glycemic control in the glucose metabolism of type 1 diabetes. The present literature shows promising results for the additional substitution of GLP-1 analogues in the treatment of type 1 diabetes mellitus. Based on the current data, there is a need to carry out large randomized-controlled trials.
authors.affiliation: Diabetes Adipositas Zentrum Zürich, Schweiz.
authors.forename: S
authors.initials: S
authors.lastname: Tölle
mesh_terms: D006801:Humans; D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage / Q000097:blood; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D007004:Hypoglycemic Agents; D007328:Insulin